



Phase angle is associated with advanced fibrosis in patients chronically infected with hepatitis C virus



Mariana de Souza Dorna^{*}, Livia Alves Amaral Santos, Fernanda Futino Gondo, Lais Augusti, Letícia de Campos Franzoni, Ligia Yukie Sassaki, Fernando Gomes Romeiro, Sergio Alberto Rupp de Paiva, Marcos Ferreira Minicucci, Giovanni Faria Silva

Department of Internal Medicine, Botucatu Medical School, UNESP – Univ Estadual Paulista, Botucatu, Brazil

ARTICLE INFO

Article history:

Received 25 June 2015

Received in revised form 5 November 2015

Accepted 15 February 2016

Available online 16 February 2016

Keywords:

Bioelectrical impedance

Hepatitis C virus

Liver fibrosis

ABSTRACT

Aims: The objective of this study was to evaluate the association of phase angle (PhA) with advanced liver fibrosis in patients chronically infected with hepatitis C virus (HCV).

Main methods: One hundred sixty consecutive patients chronically infected with HCV were treated at the Hepatitis C outpatient care setting of our hospital from April 2010 to May 2011 and prospectively evaluated. Bioelectrical impedance analysis measurements were performed during the first hospital visit. Biochemical measurements and liver biopsy data were collected from the patients' medical records and included in the analysis only if they were performed within three months of the inclusion of the patient in the study.

Key findings: One hundred sixty consecutive patients were evaluated and 25 patients were excluded. A total of 135 patients with 49.8 ± 11.4 years old were studied. Among these patients, 60% were male and the PhA was $6.5 \pm 0.8^\circ$. Regarding the stage of fibrosis, patients with advanced fibrosis were older and had more insulin resistance and more inflammation compared with patients that had mild fibrosis. Logistic regression analysis revealed that PhA was a predictor of advanced fibrosis even when adjusted for gender, age, HOMA-IR, HDL-cholesterol and AST (OR: 0.227; CI 95%: 0.090–0.569; p: 0.013). The best PhA cut-off points associated with advanced fibrosis for the combined data, for females and for males were 6.43° , 5.94° and 6.72° , respectively.

Significance: PhA was predictor of advanced liver fibrosis in patients chronically infected with HCV. In the sample evaluated, for each one-degree decrease in PhA, the risk of advanced fibrosis increased more than four-fold.

© 2016 Elsevier Inc. All rights reserved.

1. Introduction

The hepatitis C virus (HCV) was discovered more than 20 years ago, and it is still a major public health problem [1,2]. HCV affects approximately 3% of people worldwide, and the progression to advanced liver fibrosis occurs silently and over decades. The data from the literature suggest that between 10 and 40% of patients chronically infected with HCV develop cirrhosis, and among these patients, up to 4% per year develop hepatocellular carcinoma (HCC) [3,4].

In addition, there is a lack of a gold-standard nutritional assessment method for patients with liver cirrhosis. However, several studies have

suggested that bioelectrical impedance analysis (BIA) could be used to evaluate nutritional status in these patients [5,6]. BIA has been used for more than 20 years as a tool for body composition assessment. It has become popular because it is a portable, non-invasive and easy-to-use bedside method. Whole body impedance is measured mainly by the opposition of the body to an alternating current based on two components: resistance (R) and reactance (Xc) [7,8]. The phase angle (PhA) obtained from BIA is estimated by the direct ratio between R and Xc.

More recently, the use of PhA in clinical practice has increased. PhA analysis has been used as a prognostic tool in several clinical situations, such as advanced cancer, liver diseases and malnutrition [5,8,9–12]. Selberg and Selberg showed that low PhA values were associated with reduced survival in patients with liver cirrhosis [5]. In addition, in a small study, Antaki et al. determined that BIA could not distinguish between mild and advanced fibrosis in patients chronically infected with HCV [13].

^{*} Corresponding author at: Departamento de Clínica Médica, Faculdade de Medicina de Botucatu, Rubião Júnior s/n, Botucatu, SP CEP: 18618-970, Brazil.
E-mail address: marl_dorna@yahoo.com.br (M.S. Dorna).

Table 1
Demographic and laboratorial data of 135 patients chronically infected with HCV.

Variable	N = 135
Age (years)	49.8 ± 11.4
Male, n (%)	81 (60)
Phase angle (°)	6.5 ± 0.8
BMI (kg/m ²)	26.5 ± 4.8
TSF (mm)	21 (13–30)
HOMA-IR	2.8 (1.7–5.1)
AST (NxULN)	1.4 (0.8–2)
ALT (NxULN)	1.2 (0.8–1.9)
GGT (NxULN)	1.6 (0.9–2.8)
TC (mg/dL)	160.5 ± 34.7
LDL (mg/dL)	85.2 ± 29.8
HDL (mg/dL)	50.6 ± 17.2
TG (mg/dL)	105.0 (179.0–142.0)

BMI: Body Mass Index; TSF: Tricipital Skinfold Thickness; HOMA-IR: Homeostasis Model of Assessment of Insulin Resistance; AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGT: gamma-glutamyltransferase; NxULN = number of times above upper limit of normal; TC = total cholesterol; TG = triglycerides; (°): degrees. The data are expressed as the mean SD ± or median (lower-upper quartiles).

These studies suggest that PhA could be used as a prognostic tool in patients with HCV. Despite this finding, the association of PhA with disease severity in HCV patients requires further elucidation. Thus, the objective of this study was to evaluate the association of PhA with advanced liver fibrosis in patients chronically infected with HCV.

2. Materials and methods

2.1. Study design

This study was approved by the Ethics Committee of Botucatu Medical School. Written informed consent was obtained from all patients. One hundred sixty consecutive patients chronically infected with HCV who had attended the hepatitis C outpatient care setting of our hospital from April 2010 to May 2011 were prospectively evaluated. Inclusion criteria were treatment naïve patients or no treatment with PEGylated interferon and ribavirin for at least one year and the presence of liver biopsy. Exclusion criteria were ascites, hepatitis B virus infection, HIV infection, chronic kidney disease (CKD), heart failure (HF), carriers of electronic devices and metallic implants, physically disabled and pregnancy.

The Fisher and Belle formula was used to estimate the required sample size using the following variables: 25% prevalence of HCV infected patients who were evaluated for liver fibrosis; 95% confidence interval and 7.5% sample error. A total of 128 patients were included [14].

Bioelectrical impedance analysis measurements were performed during the first hospital visit. Biochemical tests and liver biopsy data were collected from the patients' medical records and included in the analysis only if they were performed within three months of the inclusion of the patient in the study.

2.2. Liver biopsy

Percutaneous liver biopsies were performed. Liver samples were considered adequate if there were at least eight complete portal tracts or if the fragment was larger than 1 cm in length. A single pathologist performed the histological analyses, and the Metavir scoring system was used to identify the amount of fibrosis or scarring: Score F0: no scarring; F1: minimal scarring; F2: scarring has occurred and extends outside the areas of the liver that contain blood vessels; F3: bridging fibrosis has spread and connected the areas that contain fibrosis; or F4: cirrhosis or advanced scarring of the liver [15,16].

2.3. Biochemical analysis

Aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyltransferase (GGT), total cholesterol (TC), triglycerides (TG), HDL-cholesterol and fasting glucose were measured as previously described [17]. LDL-cholesterol was calculated using the Friedewald formula. Fasting insulin levels were measured using a chemiluminescence immunoassay. The Homeostasis Model of Assessment of Insulin Resistance (HOMA-IR) index was calculated using the following formula: [fasting glucose (mmol/L) * fasting insulin (μU/mL) / 22.5] [18].

2.4. Bioelectrical impedance analysis

BIA was performed using tetrapolar and single-frequency equipment (Biodynamic-450, 800 μA; 50 kHz) applied to the skin using 4 adhesive electrodes on the right side of the body, with the subject lying in a supine position. All measurements were performed in the morning. The PhAs derived from the BIA were determined as previously described [19], and their values were calculated as follows: PhA = (arc tangent reactance / resistance * (180° / π)).

2.5. Statistical analysis

The data are expressed as the means ± SD or the medians (including the lower and upper quartiles). The Spearman correlation was used to evaluate the association between continuous variables with a normal distribution. Based on the liver biopsy results, the subjects were categorised into 2 groups: mild fibrosis (F0–F2) or advanced fibrosis (F3–F4). Univariate and multiple logistic regressions were used for advanced fibrosis prediction. The PhAs were included in the models as continuous independent variables and adjusted by gender, age, HOMA-IR, HDL and AST. The receiver operator characteristics (ROC) curves were used to determine the best phase angle cut-off points associated with advanced fibrosis. The data analysis was performed using Sigma Stat 3.5 for Windows (Systat Software, Inc., San Jose, CA, USA) and MedCalc (7.2). p-Values lower than 0.05 were considered statistically significant.

3. Results

One hundred sixty consecutive patients were evaluated, and 25 were excluded. The patients were assessed before nutritional evaluation, and ten patients were excluded due to uncompleted data; four due to absence of liver biopsy; eight due to the presence of ascites;

Table 2
Demographic and laboratorial data of 135 patients chronically infected with HCV according to fibrosis stage.

Variable	Mild fibrosis (F0–F2) n = 54	Advanced fibrosis (F3–F4) n = 81	p value
Age (years)	44.20 ± 11.27	53.58 ± 9.92	<0.001
Male, n (%)	31 (57.4)	50 (61.7)	0.747
PA (°)	6.81 ± 0.80	6.27 ± 0.74	<0.001
BMI (kg/m ²)	25.65 ± 4.42	27.12 ± 4.98	0.082
TSF (mm)	22.20 ± 10.46	21.74 ± 10.84	0.803
HOMA-IR	2.08 (1.38–2.93)	4.17 (2.47–6.58)	<0.001
AST (NxULN)	1.07 (0.74–1.67)	1.58 (0.82–2.09)	0.036
ALT (NxULN)	0.84 (0.58–1.23)	1.50 (0.99–2.12)	<0.001
GGT (NxULN)	1.01 (0.49–2.09)	1.81 (1.12–3.43)	<0.001
TC (mg/dL)	162.4 ± 35.3	159.2 ± 34.4	<0.001
LDL (mg/dL)	87.14 ± 29.69	83.91 ± 29.97	0.542
HDL (mg/dL)	52.69 ± 17.20	49.20 ± 17.20	0.254
TG (mg/dL)	98.0 (74.5–129)	111.5 (85.0–147.0)	0.099

PhA: phase angle; BMI: Body Mass Index; TSF: Tricipital Skinfold Thickness; HOMA-IR: Homeostasis Model of Assessment of Insulin Resistance; AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGT: gamma-glutamyltransferase; NxULN = number of times above upper limit of normal; TC = total cholesterol; TG = triglycerides; (°): degrees. The data are expressed as the mean SD ± or median (lower-upper quartiles).

Table 3

Correlation of PhA with demographic and laboratorial data of 135 patients chronically infected with HCV.

Variables	PhA total (n = 135)		PhA male (n = 81)		PhA female (n = 54)	
	r	p	r	p	r	p
Age (years)	−0.475	<0.001	−0.411	<0.001	−0.563	<0.001
BMI (kg/m ²)	0.147	0.08	0.154	0.168	0.100	0.468
TSF (mm)	−0.117	0.176	0.041	0.710	0.178	0.198
HOMA-IR	−0.107	0.222	−0.161	0.150	−0.128	0.363
AST (NxULN)	−0.220	0.011	−0.291	0.008	0.012	0.929
ALT (NxULN)	0.003	0.972	−0.072	0.522	0.223	0.112
GGT (NxULN)	−0.264	0.002	−0.348	0.001	−0.136	0.336
TC (mg/dL)	−0.144	0.096	−0.073	0.513	−0.196	0.158
LDL (mg/dL)	0.156	0.859	0.067	0.553	−0.092	0.513
HDL (mg/dL)	−0.276	0.001	−0.210	0.062	−0.081	0.567
TG (mg/dL)	0.007	0.935	0.052	0.644	−0.265	0.060

PhA: phase angle; BMI: Body Mass Index; TSF: Tricipital Skinfold Thickness; HOMA-IR: Homeostasis Model of Assessment of Insulin Resistance; AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGT: gamma-glutamyltransferase; NxULN = number of times above upper limit of normal; TC = total cholesterol; TG = triglycerides; (°): degrees.

one due to hand amputation; one due to CKD and one due to HF. A total of 135 patients with a mean age of 49.8 ± 11.4 years were evaluated. The demographic and laboratorial data are listed in Table 1. Among these patients, 60% were male, and the mean PhA was $6.5 \pm 0.8^\circ$.

Regarding the fibrosis stage, patients with advanced fibrosis were older and had more insulin resistance, as measured using HOMA-IR, compared with the patients with mild fibrosis. In addition, the group with advanced fibrosis had lower PhA values and higher levels of ALT and AST compared with the mild fibrosis group (Table 2).

Phase angle was negatively correlated with age in all studied patients, and when they were grouped according to gender. In addition, PhA was negatively correlated with AST and GGT in the combined data and in male gender. HDL was also negatively correlated with PhA but only in the combined data (Table 3) (see Table 4).

Logistic regression analysis showed that PhA was a predictor of advanced fibrosis (OR: 0.376; CI 95%: 0.222–0.639; $p < 0.001$), even when adjusted for gender, age, HOMA-IR, HDL and AST (OR: 0.227; CI 95%: 0.090–0.569; $p: 0.013$) (Table 3). Each one-degree decrease in PhA increased the risk of advance fibrosis four-fold.

The best PhA cut-off points associated with advanced fibrosis were 6.43° (AUC: 0.701; CI 95%: 0.608–0.793; $p < 0.001$) for the combined data (Fig. 1), 5.94° (AUC: 0.698; CI 95%: 0.554–0.843; $p < 0.013$) for females (Fig. 2) and 6.72° (AUC: 0.747; CI 95%: 0.629–0.866; $p < 0.001$) for males (Fig. 3).

4. Discussion

The aim of this study was to evaluate the association of PhAs with advanced liver fibrosis in patients chronically infected with HCV. Our data showed that PhA is a predictor of advanced fibrosis in HCV patients.

Advanced fibrosis, including liver cirrhosis, is one of the most important complications of HCV infection. In the United States, liver cirrhosis is the 12th most common cause of death and is characterised as an important cause of morbidity and poor life expectancy [20].

Table 4

Logistic regression models for advanced fibrosis prediction.

	Odds ratio	CI 95%	p value
Phase angle	0.376	0.222–0.639	<0.001
Phase angle ^a	0.321	0.138–0.672	0.003
Phase angle ^b	0.227	0.090–0.569	0.013

CI = confidence interval.

^a Phase angle adjusted by gender, age, HOMA-IR and HDL.

^b Phase angle adjusted by gender, age, HOMA-IR, HDL and AST.




Fig. 1. ROC curve for the association of the phase angle with advanced fibrosis for the combined data.

In HCV patients, several factors are associated with fibrosis, including older age and insulin resistance. Insulin resistance is also associated with lipoprotein profile alterations, steatosis development and reduced response to treatment in HCV patients [21]. In addition, recent evidence suggests that lipoproteins play key roles in the HCV life cycle. Indeed, HCV utilises LDL-cholesterol receptors and others receptors for hepatocyte entry and initiation of infection [22,23]. Consistent with these reports, our study demonstrated higher HOMA-IR values in patients with advanced liver fibrosis.

In our study, advanced fibrosis was also associated with inflammation, which was shown by increased levels of ALT and AST in patients. Fink and Jacobson also associated increased levels of transaminases with fibrosis progression [24]. Interestingly, increased levels of ALT and AST were correlated with hepatocyte disruption and decreased levels of cellular mass. Because PhA is inversely related to cell injuries, this finding could explain the reduced PhA values observed in patients with advanced fibrosis.

PhAs are obtained from BIA, a non-invasive and easy-to-use bedside method that evaluates body composition. Thus, PhA reduction could also be associated with malnutrition, resulting in a worse prognosis in patients with HCV. In addition to nutritional status assessment, within the last decade, PhA analysis has been used as a prognostic tool in several clinical situations, including patients with liver cirrhosis [5–12].

Kahraman et al. showed that PhA reduction in HCV patients was associated with increased adverse effects due to antiviral therapy, such as flu-like syndrome, fatigue and suppressed [11]. Selberg and Selberg [5] conducted a study with 55 patients with liver cirrhosis and found that low PhA values were associated with reduced survival in these patients [5]. In addition, in a pilot study with only twenty patients, Antaki et al.




Fig. 2. ROC curve for the association of the phase angle with advanced fibrosis for females.




Fig. 3. ROC curve for the association of the phase angle with advanced fibrosis for males.

demonstrated that BIA was not capable of distinguishing between mild and advanced fibrosis in patients chronically infected with HCV [13]. In our study we evaluated 135 HCV patients, and PhA had negative correlation with age, HDL, AST and GGT in these patients. In addition, our primary finding was that PhA was associated with advanced fibrosis in HCV patients. In addition, each one-degree decrease in PhA increased the risk of advance fibrosis more than four-fold.

Importantly, our findings could be easily used in clinical practice. On the basis of ROC curve analysis, the best PhA cut-off points associated with advanced fibrosis for the combined data, for females and for males were 6.43°, 5.94° and 6.72°, respectively.

It is important to consider some limitations of our study. Our study included a small sample size and patients from a unique medical center. It is important to notice that in our study we used a tetrapolar and single-frequency equipment instead of a multi-frequency bioelectrical impedance.

5. Conclusion

In conclusion, PhA is a predictor of advanced fibrosis in patients chronically infected with HCV. In this study, for each one-degree decrease in PhA, the risk of advance fibrosis increased more than four-fold.

Financial support

This work was supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).

Conflict of interest

None.

Authorship

MSD - study design, data collection, and writing of the manuscript. LAAS, FFG, LA, and LCF - data collection. LYS and FGR - study design.

SARP, MFM, and GFS - study design, data interpretation, and correction of the manuscript.

References

- [1] T.J. Liang, M.G. Ghany, Current and future therapies for hepatitis C virus infection, *N. Engl. J. Med.* 368 (2013) 1907–1917.
- [2] R. Williams, Global challenges in liver disease, *Hepatology* 44 (2006) 521–526.
- [3] M.G. Ghany, D.B. Strader, D.L. Thomas, et al., Diagnosis, management and treatment of hepatitis C: and update, *Hepatology* 49 (2009) 1335–1374.
- [4] T.D. Yang, L.R. Roberts, Hepatocellular carcinoma: a global view, *Nat. Rev. Gastroenterol. Hepatol.* 7 (2010) 448–458.
- [5] O. Selberg, D. Selberg, Norms and correlates of bioimpedance phase angle in healthy human subjects, hospitalized patients and patients with liver cirrhosis, *Eur. J. Appl. Physiol.* 86 (2002) 509–516.
- [6] M. Pirlich, T. Schutz, T. Spachos, et al., Bioelectrical impedance analysis is a useful bedside technique to assess malnutrition in cirrhotic patients with and without ascites, *Hepatology* 32 (2000) 1208–1215.
- [7] K. Norman, N. Stobäus, M. Pirlich, et al., Bioelectrical phase angle and impedance vector analysis – clinical relevance and applicability of impedance parameters, *Clin. Nutr.* 6 (2012) 854–861.
- [8] D. Gupta, C.G. Lis, S.L. Dalhk, et al., Bioelectrical impedance phase angle as a prognostic indicator in advanced pancreatic cancer, *Br. J. Nutrition* 92 (2004) 957–962.
- [9] A. Schwenk, A. Blisenherz, K. Romer, et al., Phase angle from bioelectrical impedance analysis remains an independent predictive marker in HIV-infected patients in the era of highly active antiretroviral treatment, *Am. J. Clin. Nutr.* 72 (2000) 496–501.
- [10] M.C. Barbosa-Silva, A.J.D. Barros, Bioelectrical impedance analysis in clinical practice: a new perspective on its use beyond body composition equations, *Curr. Opin. Clin. Nutr. Metab. Care* 8 (2005) 311–317.
- [11] A. Kahraman, J. Hilsenbeck, M. Nyga, et al., Bioelectrical impedance analysis in clinical practice: implications for hepatitis C therapy BIA and hepatitis C, *Virol. J.* 7 (2010) 191.
- [12] U.G. Kyle, L. Genton, C. Pichard, Low phase angle determined by bioelectrical impedance analysis is associated with malnutrition and nutritional risk at hospital admission, *Clin. Nutr.* 2 (2013) 294–299.
- [13] F. Antaki, M.M. French, D.K. Moonk, et al., Bioelectrical impedance analysis for the evaluation of hepatic fibrosis in patients with chronic hepatitis C infection, *Dig. Dis. Sci.* 53 (2008) 1957–1960.
- [14] L.D. Fisher, G.V. Belle, *Bioestatistics: A Methodology for Health Science*, John Wiley, New York, 1993.
- [15] G.F. Silva, K.I.R. Coelho, N.F. Nishimura, et al., Progression of liver fibrosis in blood donors infected with hepatitis c virus, *Roman J. Gastroenterol.* 13 (2004) 291–297.
- [16] P. Bedossa, T. Poynard, An algorithm of the grading of activity in chronic hepatitis C, *Hepatology* 24 (1996) 289–293.
- [17] B.P. Vogt, P.L. Souza, M.F. Minicucci, et al., Metabolic syndrome criteria as predictors of insulin resistance, inflammation and mortality in chronic hemodialysis patients, *Metab. Syndr. Relat. Disord.* 12 (2014) 443–449.
- [18] M. Romero-Gómez, M.D.M. Vilorio, R. Andrade, et al., Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients, *Gastroenterology* 128 (2005) 636–641.
- [19] U.G. Kyle, E.P. Soundar, L. Genton, et al., Can phase angle determined by bioelectrical impedance analysis assess nutritional risk? A comparison between healthy and hospitalized subjects, *Clin. Nutr.* 31 (2012) 875–881.
- [20] I. Grattagliano, E. Ubaldi, L. Bonfrate, et al., Management of liver cirrhosis between primary care and specialists, *World J. Gastroenterol.* 17 (2011) 2273–2282.
- [21] C.Y. Dai, J.F. Hwuang, M.Y. Hsieh, et al., Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients, *J. Hepatol.* 50 (2009) 712–718.
- [22] F. Negro, Abnormalities of lipid metabolism in hepatitis C virus infection, *Gut* 59 (2010) 1279–1287.
- [23] M.E. Burlone, A. Budkowska, Hepatitis C virus cell entry: role of lipoproteins and cellular receptors, *J. Gen. Virol.* 90 (2009) 1055–1070.
- [24] S.A. Fink, I.M. Jacobson, Managing patients with hepatitis-B-related or hepatitis-C-related decompensated cirrhosis, *Nat. Rev. Gastroenterol. Hepatol.* 8 (2011) 285–295.